SLC40A1 and diabetic kidney disease: Zhang et al. reported that empagliflozin attenuates tubular ferroptosis in DKD through the AMP-activated protein kinase (AMPK)/NRF2 pathway [50], and another study demonstrated that dapagliflozin could ameliorate tubular ferroptosis by stabilizing SLC40A1 [51].